Need Help?

Whole-Genome Sequencing of 128 Ashkenazi Jewish individuals

We sequenced 128 individuals of Ashkenazi Jewish ancestry. All individuals were controls in other studies: (1) Longevity (Gil Atzmon's lab; Albert Einstein College of Medicine), n=74. (2) Parkinson's disease (Lorraine Clark's lab; Columbia University Medical Center), n=54. Whole-genome, high-coverage (50x) sequencing was performed by Complete Genomics in 2012 and 2013.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000781 128
Publications Citations
Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins.
Nat Commun 5: 2014 4835
93
Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease.
PLoS One 10: 2015 e0125204
31
Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews.
Cancer Epidemiol Biomarkers Prev 26: 2017 1540-1548
4
High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation.
Hum Genet 137: 2018 343-355
16
Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia.
Neuron 109: 2021 1465-1478.e4
10
Genome-wide data from medieval German Jews show that the Ashkenazi founder event pre-dated the 14<sup>th</sup> century.
Cell 185: 2022 4703-4716.e16
3
The predictive capacity of polygenic risk scores for disease risk is only moderately influenced by imputation panels tailored to the target population.
Bioinformatics 40: 2024 btae036
0